Immuron's Travelan Hits Record Half-Year Sales

TL;DR

**Immuron's Travelan sales are booming, signaling good news for the stock!**

AI Summary

Immuron Ltd. announced on January 16, 2024, that its product, Travelan, achieved record half-yearly sales. This positive news, detailed in an announcement to the Australian Securities Exchange, indicates strong performance for one of Immuron's key products. For investors, this suggests growing demand and potential revenue growth for the company, which could positively impact its stock value.

Why It Matters

This filing indicates strong sales performance for Immuron's key product, Travelan, which could lead to increased revenue and profitability for the company.

Risk Assessment

Risk Level: low — This filing reports positive sales performance, which generally reduces investment risk by indicating business strength.

Analyst Insight

A smart investor would view this as a positive indicator of product demand and potentially consider increasing their position or initiating a new one, while still monitoring future earnings reports for sustained growth.

Key Players & Entities

• Immuron Ltd. (company) — the registrant reporting record sales
• Travelan (company) — Immuron's product achieving record half-yearly sales
• Phillip Hains (person) — Company Secretary who signed the report
• Australian Securities Exchange (company) — where Immuron published its announcement

Forward-Looking Statements

• Immuron's revenue will increase in the next earnings report due to strong Travelan sales. (Immuron Ltd.) — high confidence, target: Q2 2024 earnings report
• Investor sentiment towards Immuron will remain positive in the short term. (Immuron Ltd.) — medium confidence, target: next 3 months

FAQ

Filing Documents

• ea191644-6k_immuron.htm (6-K) — 13KB
• ea191644ex99-1_immuron.htm (EX-99.1) — 19KB
• image_001.jpg (GRAPHIC) — 1KB
• ex99-1_001.jpg (GRAPHIC) — 17KB
• ex99-1_002.jpg (GRAPHIC) — 17KB
• ex99-1_003.jpg (GRAPHIC) — 3KB
• 0001213900-24-003529.txt ( ) — 87KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on January 16, 2024 titled: - “Immuron achieves record half yearly Travelan sales” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Immuron achieves record half yearly Travelan sales 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: January 16, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR